Benutzer: Gast  Login
Titel:

Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine versus nab-paclitaxel and gemcitabine in front-line metastatic pancreatic cancer (CARRIE).

Dokumenttyp:
Journal Article; Research Support, Non-U.S. Gov't
Autor(en):
Kundranda, M; Gracian, A C; Zafar, S F; Meiri, E; Bendell, J; Algül, H; Rivera, F; Ahn, E R; Watkins, D; Pelzer, U; Charu, V; Zalutskaya, A; Kuesters, G; Pipas, J M; Santillana, S; Askoxylakis, V; Ko, A H
Abstract:
BACKGROUND: Preclinical data suggest that dual blockade of the insulin-like growth factor-1 receptor (IGF-1R) and HER3 pathways has superior activity to IGF-1R blockade alone in pancreatic ductal adenocarcinoma (PDAC). We tested whether istiratumab, an IGF-1R- and ErbB3-bispecific antibody, can enhance the efficacy of standard of care (SOC) chemotherapy in patients with metastatic PDAC selected for high IGF-1 serum levels. PATIENTS AND METHODS: CARRIE was an international, randomized, double-bli...     »
Zeitschriftentitel:
Ann Oncol
Jahr:
2020
Band / Volume:
31
Heft / Issue:
1
Seitenangaben Beitrag:
79-87
Volltext / DOI:
doi:10.1016/j.annonc.2019.09.004
PubMed:
http://view.ncbi.nlm.nih.gov/pubmed/31912800
Print-ISSN:
0923-7534
TUM Einrichtung:
Lehrstuhl für Tumormetabolismus (Prof. Algül)
 BibTeX